Overview

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The mortality of chronic heart failure patients remains high. Recombinant human Neuregulin-1 (rhNRG-1, also called Neucardin) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure and function. This study will investigate the safety and efficacy of rhNRG-1 to treat stable chronic heart failure.
Phase:
Phase 2
Details
Lead Sponsor:
Zensun Sci. & Tech. Co., Ltd.
Collaborator:
Zensun USA Inc.